Integral Health Asset Management LLC Invests $12.32 Million in Arcellx, Inc. $ACLX

Integral Health Asset Management LLC acquired a new stake in shares of Arcellx, Inc. (NASDAQ:ACLX) in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 150,000 shares of the company’s stock, valued at approximately $12,315,000. Integral Health Asset Management LLC owned 0.26% of Arcellx as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Schroder Investment Management Group purchased a new stake in Arcellx in the 2nd quarter valued at about $3,951,000. Monaco Asset Management SAM bought a new stake in Arcellx during the 3rd quarter valued at $6,452,000. Pathway Capital Management LP bought a new stake in Arcellx during the 3rd quarter valued at $4,191,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Arcellx in the 3rd quarter worth $1,273,000. Finally, American Century Companies Inc. lifted its holdings in shares of Arcellx by 694.3% in the 2nd quarter. American Century Companies Inc. now owns 431,466 shares of the company’s stock worth $28,412,000 after buying an additional 377,145 shares during the period. Hedge funds and other institutional investors own 96.03% of the company’s stock.

Analyst Ratings Changes

ACLX has been the topic of a number of research reports. Rothschild & Co Redburn downgraded shares of Arcellx from a “buy” rating to a “neutral” rating and set a $82.00 target price on the stock. in a research report on Thursday, February 12th. Needham & Company LLC downgraded Arcellx from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. Truist Financial lowered Arcellx from a “buy” rating to a “hold” rating and reduced their price target for the stock from $134.00 to $120.00 in a research report on Monday, February 23rd. TD Cowen lowered shares of Arcellx from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 2nd. Finally, Wolfe Research assumed coverage on shares of Arcellx in a report on Tuesday, November 18th. They issued a “peer perform” rating on the stock. One analyst has rated the stock with a Buy rating, seventeen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $111.87.

Insider Transactions at Arcellx

In other news, insider Rami Elghandour sold 89,916 shares of the company’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $113.92, for a total value of $10,243,230.72. Following the sale, the insider owned 276,051 shares in the company, valued at $31,447,729.92. This represents a 24.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Christopher Heery sold 7,437 shares of the firm’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $65.51, for a total value of $487,197.87. Following the sale, the insider directly owned 29,631 shares in the company, valued at approximately $1,941,126.81. This trade represents a 20.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 109,366 shares of company stock valued at $11,526,708 in the last quarter. Company insiders own 8.35% of the company’s stock.

Arcellx Stock Performance

Arcellx stock opened at $114.39 on Friday. The business’s 50-day simple moving average is $81.66 and its two-hundred day simple moving average is $79.18. The company has a market cap of $6.69 billion, a PE ratio of -28.11 and a beta of 0.23. Arcellx, Inc. has a fifty-two week low of $47.86 and a fifty-two week high of $114.80.

Arcellx (NASDAQ:ACLX) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.01) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.01). Arcellx had a negative return on equity of 55.42% and a negative net margin of 1,027.26%.The firm had revenue of $1.65 million during the quarter, compared to analysts’ expectations of $13.40 million. As a group, analysts predict that Arcellx, Inc. will post -1.58 EPS for the current fiscal year.

Arcellx Profile

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.